• The non-GAAP net income for 2004 and 2005 excluded stock-based compensation expense relating to SFAS 123(R) as we began expensing stock-based compensation on January 1, 2006.
• The non-GAAP net income for 2004 excluded a make-whole payment related to the redemption of our $345.0 million 2% convertible senior debt and a gain related to our warrants in Eyetech Pharmaceuticals, Inc. (acquired by OSI Pharmaceuticals, Inc.), which completed its initial public offering in 2004.
• The non-GAAP net income for 2005 excluded a one-time tax provision benefit related to a qualified dividend distribution made under the American Jobs Creation Act of 2004.
• The non-GAAP net income for 2006 excluded the impact of IPR&D charges of $2.39 billion associated with the acquisitions of Corus in August 2006 and Myogen in November 2006.